<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767493</url>
  </required_header>
  <id_info>
    <org_study_id>Florbetapir MS 01</org_study_id>
    <nct_id>NCT01767493</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients</brief_title>
  <official_title>An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron&#xD;
      emission tomography (PET) for assessment of demyelination in the patients with relapsing&#xD;
      remitting multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The underlying goal of this study is to assess the feasibility of [18F]Florbetapir as an&#xD;
      imaging tool to detect demyelination in the brain of MS research participants and compare to&#xD;
      similarly aged healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Lesions Detected by [18F]Florbetapir PET</measure>
    <time_frame>1 year</time_frame>
    <description>This study demonstrates the feasibility of[18F]Florbetapir PET for identifying demyelinating lesions in relapsing-remitting MS patients. It was expected that lesion size played a factor in identifying white matter lesions with those smaller than 5 mm less evident on PET. Using spherical volumes of interest the extent of reduction in the white matter uptake can be reliably quantified. This requires careful attention to techniques for sampling in both the lesions and white matter control regions for the subject.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>[18F]Florbetapir PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]Florbetapir and PET imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]Florbetapir PET imaging</intervention_name>
    <description>[18F]Florbetapir and PET imaging</description>
    <arm_group_label>[18F]Florbetapir PET imaging</arm_group_label>
    <other_name>Amyvid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility criteria (for all subjects):&#xD;
&#xD;
          -  Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information in accordance&#xD;
             with national and local subject privacy regulations&#xD;
&#xD;
          -  Willingness to comply with study procedures&#xD;
&#xD;
          -  Willingness to provide written informed consent&#xD;
&#xD;
          -  Age greater than or equal to 18 and less than or equal to 60 years old at the time of&#xD;
             the informed consent&#xD;
&#xD;
          -  Subjects of childbearing potential must practice effective contraception during the&#xD;
             study and be willing and able to continue contraception until PET testing is completed&#xD;
&#xD;
          -  For females, must be of non-childbearing potential or have a negative urine and blood&#xD;
             pregnancy test on the day of [18F]Florbetapir PET injection&#xD;
&#xD;
        Inclusion Criteria (Healthy Volunteers):&#xD;
&#xD;
          -  No history of or signs of acute or chronic neurological or psychiatric illness based&#xD;
             on evaluation by a research physician.&#xD;
&#xD;
        Inclusion Criteria (MS Subjects):&#xD;
&#xD;
          -  Have a diagnosis of relapsing remitting MS according to the 2010 MacDonald Criteria&#xD;
&#xD;
          -  Have at least 10 demyelinating lesion on brain MRI with the following characteristics:&#xD;
&#xD;
          -  Hypointense on T2 weighted images with FLAIR&#xD;
&#xD;
        Exclusion Criteria (for all subjects):&#xD;
&#xD;
          -  The subject has clinically significant abnormal laboratory value and/or clinically&#xD;
             significant unstable medical or psychiatric illness&#xD;
&#xD;
          -  The subject has evidence of clinically significant gastrointestinal, cardiovascular,&#xD;
             hepatic, renal, hematological, neoplastic, endocrine, alternative neurological (other&#xD;
             than RRMS), immunodeficiency, pulmonary, or other disorder or disease.&#xD;
&#xD;
          -  Women who are pregnant or actively breastfeeding&#xD;
&#xD;
          -  The subject has any disorder that may interfere with drug absorption, distribution,&#xD;
             metabolism, or excretion (including gastrointestinal surgery)&#xD;
&#xD;
          -  The subject has participated in another clinical study within the previous 30 days&#xD;
&#xD;
          -  Renal impairment with a creatine clearance &lt;80mL/minute at screening (creatine&#xD;
             clearance estimated by Cockcroft-Gault equation)&#xD;
&#xD;
          -  The subject is scheduled to have a major surgery or procedure during the time of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.indd.org</url>
    <description>Institute for Neurodegenerative Disorders</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <results_first_submitted>April 1, 2019</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2021</results_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>[18F]Florbetapir Imaging</title>
          <description>[18F]Florbetapir and PET imaging</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>screen failures</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>[18F]Florbetapir PET Imaging</title>
          <description>[18F]Florbetapir and PET imaging</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Lesions Detected by [18F]Florbetapir PET</title>
        <description>This study demonstrates the feasibility of[18F]Florbetapir PET for identifying demyelinating lesions in relapsing-remitting MS patients. It was expected that lesion size played a factor in identifying white matter lesions with those smaller than 5 mm less evident on PET. Using spherical volumes of interest the extent of reduction in the white matter uptake can be reliably quantified. This requires careful attention to techniques for sampling in both the lesions and white matter control regions for the subject.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[18F]Florbetapir PET Imaging</title>
            <description>[18F]Florbetapir and PET imaging</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Lesions Detected by [18F]Florbetapir PET</title>
          <description>This study demonstrates the feasibility of[18F]Florbetapir PET for identifying demyelinating lesions in relapsing-remitting MS patients. It was expected that lesion size played a factor in identifying white matter lesions with those smaller than 5 mm less evident on PET. Using spherical volumes of interest the extent of reduction in the white matter uptake can be reliably quantified. This requires careful attention to techniques for sampling in both the lesions and white matter control regions for the subject.</description>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 1 year.</time_frame>
      <desc>There were three adverse events and all three were considered to be unrelated to the imaging or other study procedures.</desc>
      <group_list>
        <group group_id="E1">
          <title>[18F]Florbetapir PET Imaging</title>
          <description>[18F]Florbetapir and PET imaging</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal Reflux</sub_title>
                <description>The adverse event was mild and deemed unrelated to imaging or other study procedures. The AE has been resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wrist Pain</sub_title>
                <description>The pain was deemed unrelated to imaging or other study procedures. The pain was mild and not limiting.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Wall Congestion</sub_title>
                <description>The adverse event was mild. The adverse event was deemed unrelated to imaging or other study procedures. The AE has been resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Pizarro</name_or_title>
      <organization>Invicro</organization>
      <phone>203-990-1613</phone>
      <email>spizarro@invicro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

